Long-acting injectable therapies extend pharmacological exposure beyond the administration event, but duration alone does not determine whether treatment remains safe, manageable, or less burdensome. Once a dose has been administered, residual exposure may continue while the patient and clinical service must manage scheduled visits, missed injections, adverse effects, monitoring, switching, and eventual discontinuation. These obligations become particularly important when a depot cannot be removed and exposure cannot be terminated promptly. Evidence from long-acting antiretroviral therapy and prevention, antipsychotics, depot buprenorphine, and longer-duration contraceptive programmes shows that extended dosing intervals can maintain efficacy and reduce administration frequency in selected populations while simultaneously creating product-specific recovery requirements and service dependencies. Missed-dose management is therefore better understood as a recovery problem defined by elapsed time, residual exposure, validated bridging or restart options, monitoring requirements, and access to an administration service. Reversibility is similarly multidimensional: withholding future injections does not eliminate exposure generated by a dose already given. Clinical value consequently depends on compatibility between pharmacokinetic persistence and the operational capacity of the treatment system surrounding it. This Perspective examines the post-administration operating problem and argues that the meaningful unit of evaluation for a long-acting injectable is not only the depot or dosing interval, but the combined product–patient–service configuration required to maintain safe treatment across the entire period of committed exposure.
